Body Composition and Epicardial Fat in Type 2 Diabetes Patients Following Insulin Detemir Versus Insulin Glargine Initiation.
The aim of the study was to compare body composition and epicardial fat thickness changes in insulin-naïve inadequately controlled patients with type 2 diabetes following basal insulin initiation with detemir vs. glargine. Six-month, open-label, interventional randomized pilot study was conducted. Dual-energy X-ray absorptiometry and echocardiography were used to estimate the body composition and epicardial fat thickness respectively. Thirty-six patients in the detemir group and 20 in the glargine group completed the study. Study groups baseline characteristics were comparable. At 6 months, for similar glycemic control, those on detemir significantly gained less total weight (0.6±2.5 vs. 4.2±4.1 kg, p=0.004), total fat mass (0.9±2.2 vs. 2.9±2.4 kg, p=0.02), and truncal fat mass (0.8±1.5 vs. 2.1±1.7 kg, p=0.02), with a loss in truncal lean mass (- 0.8±1.9 kg vs. 0.3±1.7 kg; p=0.02). EFT significantly decreased from baseline in both group (detemir - 1.7±0.52-mm, glargine - 1.1±1.6-mm; p<0.05, without significant difference inter-groups). Within the detemir group, epicardial fat thickness change correlated with truncal fat and total fat mass changes (r=0.65, p=0.06 and r=0.60, p=0.07). In conclusion, detemir resulted in less fat mass gain, a trend for a more pronounced epicardial fat thickness reduction when compared with glargine.
Department of Nutrition, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.
B
B
Elisha
Institut de Recherches Cliniques de Montréal (IRCM), Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.
M
M
Azar
Institut de Recherches Cliniques de Montréal (IRCM), Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.
N
N
Taleb
Institut de Recherches Cliniques de Montréal (IRCM), Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.
S
S
Bernard
Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL, USA.
G
G
Iacobellis
Department of Nutrition, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.
R
R
Rabasa-Lhoret
D050154:Adiposity / Q000187:drug effects; D001786:Blood Glucose / Q000276:immunology; D001823:Body Composition / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology*; D005260:Female; D006801:Humans; D000069057:Insulin Detemir / Q000494:pharmacology / Q000627:therapeutic use*; D000069036:Insulin Glargine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010496:Pericardium / Q000187:drug effects / Q000503:physiopathology*
D001786:Blood Glucose; D000069036:Insulin Glargine; D000069057:Insulin Detemir